专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

81. 发明申请

US20160069886A1 BIOMARKERS FOR EARLY DETECTION OF OVARIAN CANCER 审中-公开
公开(公告)号：US20160069886A1
公开(公告)日：2016-03-10
申请号：US14828397
申请日：2015-08-17
申请人： The Regents of the University of California
发明人： Robin Farias-Eisner , Srinivasa T. Reddy
IPC分类号： G01N33/574
CPC分类号： G01N33/57449 , C12Q1/6809 , G01N33/6893 , G01N33/721 , G01N33/78 , G01N2333/775 , G01N2333/79
摘要： Biomarker proteins that can be used in the diagnosis of early-stage ovarian cancer (OC) are described. The biomarker panels not only permit the distinction of patients with ovarian neoplasia (benign or malignant) from normal subjects, but they also allow the identification of patients with early-stage (stage I/II) ovarian cancer from those patients with benign ovarian tumors or normal individuals. The invention additionally provides methods for detecting and treating various cancers, including cancer of the ovary using OC-related molecules.

82. 发明申请

US20160054336A1 METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE 有权
标题翻译：用于诊断和预防肾损伤和肾功能衰竭的方法和组合
公开(公告)号：US20160054336A1
公开(公告)日：2016-02-25
申请号：US14673353
申请日：2015-03-30
申请人： Astute Medical, Inc.
发明人： Joseph Anderberg , Jeff Gray , Paul McPherson , Kevin Nakamura
IPC分类号： G01N33/68 , G06F19/24
CPC分类号： G01N33/6893 , G01N2333/4704 , G01N2333/4709 , G01N2333/475 , G01N2333/4753 , G01N2333/5434 , G01N2333/5446 , G01N2333/55 , G01N2333/57 , G01N2333/775 , G01N2333/96486 , G01N2333/96494 , G01N2800/347 , G06F19/24
摘要： The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Clusterin, Heart-type fatty acid binding protein, Hepatocyte growth factor, Interferon gamma, Interleukin-12 subunit beta, Interleukin-16, Interleukin-2, 72 kDa type IV collagenase, Matrix metalloproteinase-9, Midkine, and Serum amyloid P-component as diagnostic and prognostic biomarkers in renal injuries.
摘要翻译：本发明涉及用于在患有或疑似患有肾损伤的受试者中监测，诊断，预后和确定治疗方案的方法和组合物。特别地，本发明涉及使用检测一种或多种选自Clusterin，心脏型脂肪酸结合蛋白，肝细胞生长因子，干扰素γ，白细胞介素-12亚单位β，白细胞介素-16，白细胞介素-1 2,72kDa IV型胶原酶，基质金属蛋白酶-9，Midkine和血清淀粉样蛋白P组分作为肾损伤的诊断和预后生物标志物。

83. 发明申请

US20160003819A1 RAPID TESTS FOR INSURANCE UNDERWRITING 审中-公开
标题翻译：保险承诺的快速检测
公开(公告)号：US20160003819A1
公开(公告)日：2016-01-07
申请号：US14427972
申请日：2013-09-11
申请人： FORCE DIAGNOSTICS, INC
发明人： Michael P. CURRAN , David H. OSTROW , Brian MULCONREY , Tedd C. DETERMAN
IPC分类号： G01N33/558 , G01N33/72 , G01N33/68 , G01N33/569 , G01N33/576
CPC分类号： G01N33/558 , G01N33/56988 , G01N33/57434 , G01N33/576 , G01N33/6854 , G01N33/723 , G01N2333/4737 , G01N2333/58 , G01N2333/775 , G01N2800/08
摘要： The present invention relates to rapid test devices, kits and systems comprising the rapid test devices for assessing at least two analytes in a sample derived from a life or health insurance applicant, said at least two analytes being selected from the group consisting of a human immunodeficiency virus (HIV) antigen (e.g., a HIV polypeptide), a HIV polynucleotide, an anti-HIV antibody, a hepatitis C virus (HCV) antigen (e.g., a HCV polypeptide), a HCV polynucleotide, an anti-HCV antibody, a liver enzyme alanine transaminase (ALT), a liver enzyme aspartate transaminase (AST), nt-probnp (or NT-proBNP), probnp (or proBNP), cotinine, nicotine, cocaine, a metabolite of cocaine (e.g., benzoylecgonine), pro state-specific antigen (PSA), apolipoprotein A-1 (ApoA1), apolipoprotein B (ApoB), Hemoglobin Ale and high-sensitivity C-reactive protein (hsCRP). The present invention also relates to methods for using the rapid test devices, kits and systems as part of the assessment of the life or health insurance applications.
摘要翻译：本发明涉及快速测试装置，试剂盒和系统，其包括用于评估来自生命或健康保险申请人的样品中的至少两种分析物的快速测试装置，所述至少两种分析物选自人免疫缺陷病毒（HIV）抗原（例如，HIV多肽），HIV多核苷酸，抗HIV抗体，丙型肝炎病毒（HCV）抗原（例如，HCV多肽），HCV多核苷酸，抗HCV抗体，肝酶丙氨酸转氨酶（ALT），肝酶天冬氨酸转氨酶（AST），nt-probnp（或NT-proBNP），probnp（或proBNP），可替宁，尼古丁，可卡因，可卡因的代谢物（例如苯并恶唑）状态特异性抗原（PSA），载脂蛋白A-1（ApoA1），载脂蛋白B（ApoB），血红蛋白Ale和高敏C反应蛋白（hsCRP）。本发明还涉及使用快速测试装置，套件和系统作为对生命或健康保险应用的评估的一部分的方法。

84. 发明申请

US20150368715A1 DIAGNOSTIC AND TREATMENT OF CHRONIC HEART FAILURE 审中-公开
标题翻译：慢性心脏衰竭的诊断和治疗
公开(公告)号：US20150368715A1
公开(公告)日：2015-12-24
申请号：US14749723
申请日：2015-06-25
申请人： Fatima SMIH , Philippe ROUET
发明人： Fatima SMIH , Philippe ROUET
IPC分类号： C12Q1/68 , G01N33/92
CPC分类号： C12Q1/6883 , C12N15/113 , C12Q2600/158 , G01N33/92 , G01N2333/775 , G01N2800/325
摘要： The invention relates to Apolipoprotein O (Apo O) as a biomarker for chronic heart failure. Moreover, the invention relates to a compound which may be an inhibitor of Apo O activity or an inhibitor of the Apo O gene expression for use in the treatment of chronic heart failure.
摘要翻译：本发明涉及载脂蛋白O（Apo O）作为慢性心力衰竭的生物标志物。此外，本发明涉及可以是Apo O活性抑制剂的化合物或用于治疗慢性心力衰竭的Apo O基因表达的抑制剂。

85. 发明申请

US20150337375A1 BIOMARKERS FOR CHRONIC TRAUMATIC ENCEPHALOPATHY 审中-公开
标题翻译：生物标志物治疗慢性肠胃炎
公开(公告)号：US20150337375A1
公开(公告)日：2015-11-26
申请号：US14652630
申请日：2013-12-20
申请人： The Trustees of Columbia University in the City of New York
发明人： John Crary , Ann MCKEE
IPC分类号： C12Q1/68 , A61K31/7105 , A61K31/713 , G01N33/68
CPC分类号： C12Q1/6883 , A61K31/7105 , A61K31/713 , C12Q2600/156 , C12Q2600/172 , G01N33/6896 , G01N2333/775 , G01N2500/04 , G01N2800/2814
摘要： This invention relates to the field of screening for, identifying, diagnosing, and prognosing chronic traumatic encephalopathy (CTE). Specifically, this invention provides various biomarkers for this disease, and methods of using these biomarkers to correctly diagnose, prognose and predict those individuals who would develop CTE after suffering from mild traumatic brain injury. The invention also provides targets for drug development and basic research for CTE and preventative and therapeutic agents for CTE.
摘要翻译：本发明涉及慢性创伤性脑病（CTE）的筛选，鉴定，诊断和预后领域。具体地，本发明提供了用于该疾病的各种生物标志物，以及使用这些生物标志物来正确地诊断，预测和预测在遭受轻度创伤性脑损伤后发展CTE的那些个体的方法。本发明还提供了用于CTE和CTE的预防和治疗剂的药物开发和基础研究的目标。

86. 发明授权

US09068990B2 Methods of predicting and decreasing the risk of pregnancy loss 有权
标题翻译：预防和减少妊娠损失风险的方法
公开(公告)号：US09068990B2
公开(公告)日：2015-06-30
申请号：US14276601
申请日：2014-05-13
申请人： University of Louisville Research Foundation, Inc.
发明人： Douglas D. Taylor , Cicek Gercel-Taylor
IPC分类号： G01N33/68
CPC分类号： G01N33/689 , G01N2333/775 , G01N2333/78 , G01N2800/50
摘要： Described are methods for diagnosing and predicting the risk of pregnancy loss in a subject based on the presence of an aberrant humoral response to three proteins, Apolipoprotein B-100, alpha2macrogloblin (alpha2M), and fibronectin. The presence or a detectable level of maternal IgG antibodies to trophoblast-derived fibronectin and/or ApoB-100, and/or the absence or a non-detectable level of antibodies specifically binding to alpha2M is associated with a history of RPL and an increased risk of pregnancy loss. Also described are methods for identifying subjects at risk of pregnancy loss, selecting subjects for participation in a clinical study, and methods of decreasing the risk of pregnancy loss in a subject which include detecting the presence or absence of antibodies to one or more of trophoblast-derived ApoB-100, alpha2M, and fibronectin. Also provided are kits that contain ApoB-100, alpha2M, and fibronectin.
摘要翻译：基于对三种蛋白质，载脂蛋白B-100，α2巨蛋白酶（α2M）和纤连蛋白的异常体液应答的存在，描述了用于诊断和预测受试者的妊娠损失风险的方法。来自滋养细胞衍生的纤连蛋白和/或ApoB-100的母体IgG抗体的存在或可检测水平，和/或与α2M特异性结合的不存在或不可检测水平的抗体与RPL的历史和增加的风险相关的怀孕损失。还描述了用于鉴定患有妊娠损失风险的受试者的方法，选择参与临床研究的受试者以及降低受试者妊娠损失风险的方法，其中包括检测对滋养层细胞的一种或多种的抗体的存在或不存在，衍生的ApoB-100，α2M和纤连蛋白。还提供了含有ApoB-100，α2M和纤连蛋白的试剂盒。

87. 发明申请

US20150133378A1 METHOD FOR PREDICTING RISK OF EXPOSURE TO INTERSTITIAL FIBROSIS AND TUBULAR ATROPHY WITH CLUSTERIN 有权
标题翻译：用CLUSTERIN预测暴露于间质纤维化和管状ATROPHY的风险的方法
公开(公告)号：US20150133378A1
公开(公告)日：2015-05-14
申请号：US14394965
申请日：2013-04-17
申请人： ICHAN SCHOOL OF MEDICINE AT MOUNT SINAI
发明人： Barbara Murphy , Philip J. O'Connell
IPC分类号： G01N33/53
CPC分类号： G01N33/5308 , C07K14/47 , G01N33/6893 , G01N2333/775 , G01N2800/085 , G01N2800/245 , G01N2800/50 , G01N2800/54
摘要： A method for identifying a kidney transplant recipient at an increased risk of developing interstitial fibrosis or tubular atrophy which comprises obtaining a post-transplant urine sample from the kidney transplant recipient; measuring the level of clusterin in the urine sample; comparing the level of clusterin in the patient sample to the level of clusterin in a control sample from the urine of a non-fibrotic kidney transplant recipient; diagnosing a kidney transplant recipient with a clusterin level that is significantly higher than the clusterin level in the control as being at an increased risk of developing interstitial fibrosis or tubular atrophy.
摘要翻译：一种识别肾移植接受者的方法，所述方法包括从肾移植接受者获得移植后尿液样品，所述方法包括发生间质纤维化或管状萎缩的风险增加。测量尿样中的聚集蛋白水平; 将患者样品中的聚集蛋白水平与非纤维化肾脏移植受体的尿液对照样品中的聚集蛋白水平进行比较; 诊断肾移植受者具有明显高于对照组的簇蛋白水平的簇蛋白水平，因为发展间质性纤维化或肾小管萎缩的风险增加。

88. 发明申请

US20150072879A1 METHODS FOR IMPROVING INFLAMMATORY BOWEL DISEASE DIAGNOSIS 审中-公开
标题翻译：用于改善炎症性腹膜疾病诊断的方法
公开(公告)号：US20150072879A1
公开(公告)日：2015-03-12
申请号：US14229715
申请日：2014-03-28
申请人： NESTEC S.A.
发明人： Fred Princen , Steven Lockton , Lisa J. Croner , Frederick A. Fletcher , Thomas Stockfisch , Sharat Singh
IPC分类号： G06F19/00 , G01N33/543 , C12Q1/68
CPC分类号： G01N33/54306 , C12Q1/6883 , C12Q2600/112 , C12Q2600/156 , C12Q2600/158 , G01N33/6854 , G01N33/6893 , G01N2333/4737 , G01N2333/49 , G01N2333/70525 , G01N2333/70542 , G01N2333/775 , G01N2800/065 , G01N2800/60 , G16B20/00 , G16B40/00 , G16H50/30 , Y02A90/24 , Y02A90/26
摘要： The present invention provides methods and systems to predict and diagnose inflammatory bowel disease (IBD) and subtypes such as ulcerative colitis (UC) and Crohn's disease (CD) by detecting the presence, absence, level, and/or genotype of one or more sero-genetic-inflammation markers. Advantageously, with the present invention, it is possible to provide a diagnosis of IBD versus non-IBD, to rule out IBD that is inconclusive for CD and UC, and to differentiate between CD and UC with increased accuracy.
摘要翻译：本发明提供通过检测一种或多种血清的存在，不存在，水平和/或基因型来预测和诊断炎症性肠病（IBD）和亚型如溃疡性结肠炎（UC）和克罗恩病（CD）的方法和系统遗传炎症标志物。有利的是，利用本发明，可以提供IBD与非IBD的诊断，以排除对于CD和UC不确定的IBD，并且以更高的精度区分CD和UC。

89. 发明申请

US20150037905A1 RISK MARKERS FOR CARDIOVASCULAR DISEASE 审中-公开
标题翻译：心血管疾病危险标志
公开(公告)号：US20150037905A1
公开(公告)日：2015-02-05
申请号：US14275307
申请日：2014-05-12
申请人： THE CLEVELAND CLINIC FOUNDATION
发明人： Stanley L. Hazen , Michael Kinter , Marc S. Penn , Jonathan Smith , Lemin Zheng
IPC分类号： G01N33/561 , C07K16/18
CPC分类号： G01N33/561 , C07K16/18 , G01N33/6893 , G01N33/92 , G01N2333/775 , G01N2800/32
摘要： Provided herein methods for determining whether a subject, particularly a human subject, is at risk of developing, having, or experiencing a complication of cardiovascular disease, and methods of treating subjects who are identified by the current methods of being at risk for cardiovascular disease. In one embodiment, the method comprises determining levels of one or more oxidized apolipoprotein A-I related biomolecules in a bodily sample from the subject. Also, provided are kits and reagents for use in the present methods. Also provided are methods for monitoring the status of cardiovascular disease in a subject or the effects of therapeutic agents on subjects with cardiovascular disease. Such method comprising determining levels of one or more oxidized apolipoprotein A-I related molecules in bodily samples taken from the subject over time or before and after therapy.
摘要翻译：本文提供用于确定受试者，特别是人类受试者是否处于发展，具有或经历心血管疾病并发症的风险的方法，以及治疗由目前的心血管疾病风险的方法鉴定的受试者的方法。在一个实施方案中，该方法包括确定来自受试者的身体样品中一种或多种氧化的载脂蛋白A-1相关生物分子的水平。此外，提供了用于本方法的试剂盒和试剂。还提供了用于监测受试者心血管疾病状态或治疗剂对心血管疾病受试者的影响的方法。这种方法包括测定在受试者随时间或治疗之前或之后取自受试者的身体样品中一种或多种氧化的载脂蛋白A-1相关分子的水平。

90. 发明申请

US20140356348A1 METHODS OF PREDICTING AND DECREASING THE RISK OF PREGNANCY LOSS 有权
标题翻译：预防和减少PREGNANCY损失风险的方法
公开(公告)号：US20140356348A1
公开(公告)日：2014-12-04
申请号：US14276601
申请日：2014-05-13
申请人： University of Louisville Research Foundation, Inc.
发明人： Douglas D. Taylor , Cicek Gercel-Taylor
IPC分类号： G01N33/68
CPC分类号： G01N33/689 , G01N2333/775 , G01N2333/78 , G01N2800/50
摘要： Described are methods for diagnosing and predicting the risk of pregnancy loss in a subject based on the presence of an aberrant humoral response to three proteins, Apolipoprotein B-100, alpha2macrogloblin (alpha2M), and fibronectin. The presence or a detectable level of maternal IgG antibodies to trophoblast-derived fibronectin and/or ApoB-100, and/or the absence or a non-detectable level of antibodies specifically binding to alpha2M is associated with a history of RPL and an increased risk of pregnancy loss. Also described are methods for identifying subjects at risk of pregnancy loss, selecting subjects for participation in a clinical study, and methods of decreasing the risk of pregnancy loss in a subject which include detecting the presence or absence of antibodies to one or more of trophoblast-derived ApoB-100, alpha2M, and fibronectin. Also provided are kits that contain ApoB-100, alpha2M, and fibronectin.
摘要翻译：基于对三种蛋白质，载脂蛋白B-100，α2巨蛋白酶（α2M）和纤连蛋白的异常体液应答的存在，描述了用于诊断和预测受试者的妊娠损失风险的方法。来自滋养细胞衍生的纤连蛋白和/或ApoB-100的母体IgG抗体的存在或可检测水平，和/或与α2M特异性结合的不存在或不可检测水平的抗体与RPL的历史和增加的风险相关的怀孕损失。还描述了用于鉴定患有妊娠损失风险的受试者的方法，选择参与临床研究的受试者以及降低受试者妊娠损失风险的方法，其中包括检测对滋养层细胞的一种或多种的抗体的存在或不存在，衍生的ApoB-100，α2M和纤连蛋白。还提供了含有ApoB-100，α2M和纤连蛋白的试剂盒。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式